At a high school pep rally you would expect to see cheerleaders and mascots, but you wouldn’t expect to see a 6-year-old. On Wednesday at Grandview High school in Aurora, their guest of honor was 6-year-old Maxwell Freed. “Having him back was really special to us,” said senior class president,...
Latest News
Colorectal cancer rates are rising in adults under age 50 — people who are not typically screened for such cancers. The finding, gleaned from a cancer surveillance database and published in the June issue of Cancer Epidemiology Biomarkers & Prevention, reported a 17% increase in this age group over a...
NEW YORK, NY — Columbia University scientists have been awarded a $15 million grant from the NIH’s Ultra-rare Gene-based Therapy Network to design tailor-made gene-based therapies for nine people with rare forms of amyotrophic lateral sclerosis (ALS). Gene-based therapies for ALS have potential for the approximately one in eight patients...
NEW YORK, NY — Columbia researchers have discovered a genetic variant that reduces the odds of developing Alzheimer’s disease by up to 70% and may be protecting thousands of people in the United States from the disease. The discovery of the protective variant, which appears to allow toxic forms of...
New York, NY – Body dysmorphic disorder (BDD) is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one’s physical appearance. Patients with BDD often have distorted self-image, intrusive thoughts, and compulsive behaviors that significantly impair daily functioning and quality of life. Current therapies have limited...
Baltimore, Maryland – A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) — soft tissue tumors that are stubbornly resistant to chemotherapy and radiation — according to a laboratory study led by researchers at the Johns Hopkins Kimmel Cancer Center. Both drugs interfere...
MIAMI, FLORIDA – Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma. Based on...
Bethesda, Maryland – Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse...
According to the results of a phase 1/2 study, combination therapy with the mTOR inhibitor temsirolimus and the immunomodulatory agent lenalidomide (TEM/LEN) was feasible and demonstrated activity in heavily pretreated lymphomas, including relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The open-label, multicenter, phase 1/2 study (ClinicalTrials.gov identifier: NCT01076543) accrued patients with R/R...
Birmingham, England – Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found. The results of the BEACON trial conducted by the Cancer Research UK Clinical Trials Unit at the...